Alexza Pharmaceuticals IncFind Ratings Reports
ALEXZA PHARMACTCLS INC's gross profit margin for the first quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. ALEXZA PHARMACTCLS INC has very weak liquidity. Currently, the Quick Ratio is 0.07 which clearly shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 43.87% from the same quarter last year. The key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY16||Q1 FY15|
|Net Sales ($mil)||0.72||0.71|
|Net Income ($mil)||-3.36||-0.4|
|Balance Sheet||Q1 FY16||Q1 FY15|
|Cash & Equiv. ($mil)||4.5||22.52|
|Total Assets ($mil)||10.58||43.17|
|Total Debt ($mil)||67.95||64.16|
|Profitability||Q1 FY16||Q1 FY15|
|Gross Profit Margin||-622.78||-1204.26|
|Return on Assets||-229.31||-61.15|
|Return on Equity||0.0||0.0|
|Debt||Q1 FY16||Q1 FY15|
|Share Data||Q1 FY16||Q1 FY15|
|Shares outstanding (mil)||21.75||19.42|
|Div / share||0.0||0.0|
|Book value / share||-3.42||-2.66|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||145364.0||210637.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.
|ALXA NM||Peers 42.37||ALXA NM||Peers 27.40|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
ALXA's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
ALXA's P/CF is negative making the measure meaningless.
|ALXA NA||Peers 15.45||ALXA NA||Peers 0.53|
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.
Ratio not available.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|ALXA NM||Peers 7.51||ALXA 18.25||Peers -19.42|
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ALXA's P/B is negative making this valuation measure meaningless.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
ALXA is expected to have an earnings growth rate that significantly exceeds its peers.
|ALXA 3.97||Peers 22.36||ALXA 22.95||Peers 3.12|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ALXA is trading at a significant discount to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
ALXA has a sales growth rate that significantly exceeds its peers.